IDH1 and neoplasm: IDH1-mutant tumours exacerbate immune suppression through metabolic reprogramming, increasing the production of metabolites such as 2-HG, which inhibits the function of TET2 and reduces T-cell activation, contributing to resistance against ICIs (68–70).